Novartis India Limited (NOVARTIND.BO)
INR 998.85
(-1.78%)
INR 998.85
(-1.78%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 50.7 Million INR | -70.85% |
| 2022 | 173.9 Million INR | -4.82% |
| 2021 | 182.7 Million INR | -63.3% |
| 2020 | 497.8 Million INR | -11.83% |
| 2019 | 564.6 Million INR | 0.0% |
| 2018 | - INR | 0.0% |
| 2017 | - INR | 0.0% |
| 2016 | - INR | 0.0% |
| 2015 | - INR | 0.0% |
| 2014 | - INR | 0.0% |
| 2013 | - INR | 0.0% |
| 2012 | - INR | -100.0% |
| 2011 | 1.4 Million INR | 0.0% |
| 2010 | - INR | -100.0% |
| 2009 | 2.69 Million INR | -9.73% |
| 2008 | 2.98 Million INR | -32.21% |
| 2007 | 4.39 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - INR | 0.0% |
| 2024 Q1 | - INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 64.3 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 50.7 Million INR | 0.0% |
| 2023 FY | 50.7 Million INR | -70.85% |
| 2022 Q2 | 184.7 Million INR | 0.0% |
| 2022 FY | 173.9 Million INR | -4.82% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 173.9 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q4 | 182.7 Million INR | 0.0% |
| 2021 Q2 | 465.3 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 182.7 Million INR | -63.3% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 497.8 Million INR | -11.83% |
| 2020 Q2 | 535.5 Million INR | 0.0% |
| 2020 Q4 | 497.8 Million INR | 0.0% |
| 2019 Q1 | - INR | 0.0% |
| 2019 FY | 564.6 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 567.4 Million INR | 0.0% |
| 2019 Q4 | 564.6 Million INR | 0.0% |
| 2018 Q3 | - INR | 0.0% |
| 2018 Q2 | - INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2018 FY | - INR | 0.0% |
| 2018 Q4 | - INR | 0.0% |
| 2017 Q4 | - INR | 0.0% |
| 2017 Q3 | - INR | 0.0% |
| 2017 FY | - INR | 0.0% |
| 2017 Q1 | - INR | 0.0% |
| 2017 Q2 | - INR | 0.0% |
| 2016 Q1 | - INR | 0.0% |
| 2016 Q4 | - INR | 0.0% |
| 2016 Q2 | - INR | 0.0% |
| 2016 FY | - INR | 0.0% |
| 2016 Q3 | - INR | 0.0% |
| 2015 Q4 | - INR | 0.0% |
| 2015 FY | - INR | 0.0% |
| 2015 Q3 | - INR | 0.0% |
| 2015 Q2 | - INR | 0.0% |
| 2015 Q1 | - INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2014 FY | - INR | 0.0% |
| 2014 Q4 | - INR | 0.0% |
| 2014 Q3 | - INR | 0.0% |
| 2014 Q2 | - INR | 0.0% |
| 2013 Q2 | - INR | 0.0% |
| 2013 Q4 | - INR | 0.0% |
| 2013 FY | - INR | 0.0% |
| 2013 Q3 | - INR | 0.0% |
| 2013 Q1 | - INR | 0.0% |
| 2012 FY | - INR | -100.0% |
| 2012 Q4 | - INR | 0.0% |
| 2012 Q2 | 1.2 Million INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2011 Q4 | 1.4 Million INR | 0.0% |
| 2011 FY | 1.4 Million INR | 0.0% |
| 2010 FY | - INR | -100.0% |
| 2009 FY | 2.69 Million INR | -9.73% |
| 2008 FY | 2.98 Million INR | -32.21% |
| 2007 FY | 4.39 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 235.2 Million INR | 78.444% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -262.973% |
| Sigachi Industries Limited | 265.79 Million INR | 80.925% |
| Bal Pharma Limited | 363.82 Million INR | 86.065% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | 54.58% |
| Medico Remedies Limited | 8.67 Million INR | -484.64% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Venus Remedies Limited | 386.8 Million INR | 86.892% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | 52.439% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 96.387% |
| Shilpa Medicare Limited | 5.6 Billion INR | 99.095% |
| Aarti Drugs Limited | 2.75 Billion INR | 98.159% |
| Lupin Limited | 1.55 Billion INR | 96.735% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 99.763% |
| Zydus Lifesciences Limited | 251 Million INR | 79.801% |
| Windlas Biotech Limited | 20.18 Million INR | -151.239% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Eris Lifesciences Limited | 6.54 Billion INR | 99.225% |
| Valiant Laboratories Limited | 746.63 Million INR | 93.209% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 78.553% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 95.209% |
| Ipca Laboratories Limited | 5.8 Billion INR | 99.126% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 85.755% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -281.203% |
| Bajaj HealthCare Limited | 650.34 Million INR | 92.204% |
| RPG Life Sciences Limited | -30.3 Million INR | 267.327% |
| Mankind Pharma Limited | 248.67 Million INR | 79.612% |
| Laurus Labs Limited | 8.6 Billion INR | 99.411% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.796% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 4259.147% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 99.684% |
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 91.937% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 96.658% |
| Unichem Laboratories Limited | 382.22 Million INR | 86.735% |
| Sequent Scientific Limited | 1.42 Billion INR | 96.448% |
| Wanbury Limited | 820 Million INR | 93.817% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 76.125% |
| Wockhardt Limited | 8.91 Billion INR | 99.431% |
| Themis Medicare Limited | 267.74 Million INR | 81.064% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | 32.91% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.84% |
| Glenmark Life Sciences Limited | 147.61 Million INR | 65.653% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 99.154% |
| Divi's Laboratories Limited | 20 Million INR | -153.5% |
| NATCO Pharma Limited | 53 Million INR | 4.34% |
| Gufic Biosciences Limited | 1.53 Billion INR | 96.707% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 99.498% |
| Procter & Gamble Health Limited | 68.8 Million INR | 26.308% |
| FDC Limited | 2.46 Million INR | -1955.961% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 97.237% |
| Granules India Limited | 689.71 Million INR | 92.649% |
| Medicamen Biotech Limited | 12.55 Million INR | -303.823% |
| Alkem Laboratories Limited | 400 Million INR | 87.325% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -82.138% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -1322.16% |
| Megasoft Limited | 1.35 Billion INR | 96.264% |
| ZIM Laboratories Limited | 356 Million INR | 85.759% |
| Strides Pharma Science Limited | 6.71 Billion INR | 99.245% |
| Neuland Laboratories Limited | 449.2 Million INR | 88.713% |
| Morepen Laboratories Limited | 33.64 Million INR | -50.713% |
| Hikal Limited | 4.22 Billion INR | 98.801% |
| Indoco Remedies Limited | 3.51 Billion INR | 98.559% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -12575.0% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | 62.034% |
| Hester Biosciences Limited | 1.81 Billion INR | 97.211% |